Sign Up to like & get
recommendations!
0
Published in 2018 at "Journal francais d'ophtalmologie"
DOI: 10.1016/j.jfo.2018.02.001
Abstract: New anticancer therapies, immune pathway inhibitors, may cause immune-related adverse events (IRAE). Immune-related ocular toxicities are rare but are potentially serious adverse events. The purpose of this article is to report a case of ocular…
read more here.
Keywords:
nivolumab therapy;
uveitis associated;
associated nivolumab;
therapy ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Ocular immunology and inflammation"
DOI: 10.1080/09273948.2021.1872649
Abstract: PURPOSE The immune checkpoint inhibitors (ICPIs) comprise a class of oncologic immunotherapies. The most recent US Food and Drug Administration-approved ICPI is cemiplimab (Libtayo®). Cemiplimab, like the other ICPIs, blocks checkpoint receptors in order to…
read more here.
Keywords:
posterior uveitis;
treatment;
cemiplimab;
associated cemiplimab ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.4425
Abstract: Background Uveitis is one of the most common extra-articular manifestations of patients with spondyloarthritis (SpA). In severe cases, uveitis may require the use of biological therapy, primarily tumor necrosis factors inhibitors (TNFi), being the most…
read more here.
Keywords:
spa;
certolizumab pegol;
treatment;
uveitis associated ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2022 at "BMJ Case Reports"
DOI: 10.1136/bcr-2021-244196
Abstract: Ocular symptoms are a common reason for patients to present to the emergency department or to their primary care physician. Though often benign, these symptoms can also be an early manifestation of systemic disease. We…
read more here.
Keywords:
uveitis associated;
tattoo granulomas;
granulomas uveitis;
associated tattoo ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Immunotherapy"
DOI: 10.2217/imt-2021-0032
Abstract: Background: We report the long-term outcome of uveitis associated with cancer immunotherapy (CIT). Methods: This retrospective review included serial patients with CIT-associated uveitis treated using various regimen. Results: Eight patients treated with rituximab (anti-CD20), nivolumab (anti-PD-1), ipilimumab (anti-CTLA-4),…
read more here.
Keywords:
immunotherapy;
long term;
uveitis associated;
cancer immunotherapy ... See more keywords